CoChat

Lixisenatide Reduces Chylomicron Triacylglycerol by Increased Clearance

Open access
Whyte, Martin B, Shojaee-Moradie, Fariba, Sharaf, Sharaf E, Jackson, Nicola C, Fielding, Barbara, Hovorka, Roman, Mendis, Jeewaka, Russell-Jones, David, Umpleby, A Margot · 2019 · The Journal of Clinical Endocrinology & Metabolism

The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.

Abstract

Context: Glucagon-like peptide-1 (GLP-1) agonists control postprandial glucose and lipid excursion in type 2 diabetes; however, the mechanisms are unclear. Objective: To determine the mechanisms of postprandial lipid and glucose control with lixisenatide (GLP-1 analog) in type 2 diabetes. Design: Randomized, double-blind, cross-over study. Setting: Centre for Diabetes, Endocrinology, and Research, Royal Surrey County Hospital, Guildford, United Kingdom. Patients: Eight obese men with type 2 diabetes [age, 57.3 ± 1.9 years; body mass index, 30.3 ± 1.0 kg/m2; glycosylated hemoglobin, 66.5 ± 2.6 mmol/mol (8.2% ± 0.3%)]. Interventions: Two metabolic studies, 4 weeks after lixisenatide or placebo, with cross-over and repetition of studies. Main Outcome Measures: Study one: very-low-density lipoprotein (VLDL) and chylomicron (CM) triacylglycerol (TAG) kinetics were measured with an IV bolus of [2H5]glycerol in a 12-hour study, with hourly feeding. Oral [13C]triolein, in a single meal, labeled enterally derived TAG. Study two: glucose kinetics were measured with [U-13C]glucose in a mixed-meal (plus acetaminophen to measure gastric emptying) and variable IV [6,6-2H2]glucose infusion. Results: Study one: CM-TAG (but not VLDL-TAG) pool-size was lower with lixisenatide (P = 0.046). Lixisenatide reduced CM [13C]oleate area under the curve (AUC)60–480min concentration (P = 0.048) and increased CM-TAG clearance, with no effect on CM-TAG production rate. Study two: postprandial glucose and insulin AUC0–240min were reduced with lixisenatide (P = 0.0051; P < 0.05). Total glucose production (P = 0.015), rate of glucose appearance from the meal (P = 0.0098), and acetaminophen AUC0–360min (P = 0.006) were lower with lixisenatide than with placebo. Conclusions: Lixisenatide reduced [13C]oleate concentrations, derived from a single meal in CM-TAG and glucose rate of appearance from the meal through delayed gastric emptying. However, day-long CM production, measured with repeated meal feeding, was not reduced by lixisenatide and decreased CM-TAG concentration resulted from increased CM-TAG clearance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2018-01176

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. (A) Plasma TAG, (B) TRL-TAG, (C) VLDL-TAG, and (D) CM-TAG concentrations (mmol/L) at fasting (−240 minutes) and after meal drinks at 1-hour intervals (−240 to 480 minutes) at the end of 4 weeks of treatment with either lixisenatide (white circles) or placebo (black circles) (study one). Lixisenatide or placebo injection was self-administered at −270 minutes. The results are presented as mean ± SEM. Black arrows indicate hourly meals; narrow gray arrows, the meal labeled with [1,1,1 13C3]triolein; and wide gray arrows, the bolus of [1,1,2,3,3 2H5]glycerol administered at the start of steady-state. *P < 0.05.
Figure 1. (A) Plasma TAG, (B) TRL-TAG, (C) VLDL-TAG, and (D) CM-TAG concentrations (mmol/L) at fasting (−240 minutes) and after meal drinks at 1-hour intervals (−240 to 480 minutes) at the end of 4 weeks of treatment with either lixisenatide (white circles) or placebo (black circles) (study one). Lixisenatide or placebo injection was self-administered at −270 minutes. The results are presented as mean ± SEM. Black arrows indicate hourly meals; narrow gray arrows, the meal labeled with [1,1,1 13C3]triolein; and wide gray arrows, the bolus of [1,1,2,3,3 2H5]glycerol administered at the start of steady-state. *P < 0.05.CC BY · PubMed Central
Figure 2. (A) CM [13C]oleate concentration (µmol/L) at fasting (−240 minutes) and after meal drinks at 1-hour intervals (−240 to 480 minutes) at the end of 4 weeks of treatment with either lixisenatide (white circles) or placebo (black circles) (study one). [13C]oleate was mixed with the third meal (−120 minutes). The lixisenatide or placebo injection was self-administered at −270 minutes. (B) FCR of VLDL-TAG and CM-TAG (pools per day). (C) Production rate of VLDL-TAG and CM-TAG (mg/d/kg body weight). The results are presented as mean ± SEM. *P < 0.05.
Figure 2. (A) CM [13C]oleate concentration (µmol/L) at fasting (−240 minutes) and after meal drinks at 1-hour intervals (−240 to 480 minutes) at the end of 4 weeks of treatment with either lixisenatide (white circles) or placebo (black circles) (study one). [13C]oleate was mixed with the third meal (−120 minutes). The lixisenatide or placebo injection was self-administered at −270 minutes. (B) FCR of VLDL-TAG and CM-TAG (pools per day). (C) Production rate of VLDL-TAG and CM-TAG (mg/d/kg body weight). The results are presented as mean ± SEM. *P < 0.05.CC BY · PubMed Central
Figure 3. (A) Plasma glucose, (B) glucagon, (C) TAG, (D) NEFA, (E) acetaminophen, and (F) insulin (pmol/L) at fasting (−120 to 0 minutes) and in response to a mixed meal and acetaminophen (consumed at 0 minutes) at the end of 4 weeks of treatment with either lixisenatide (white circles) or placebo (black circles) (study two). The lixisenatide or placebo injection was self-administered at −30 minutes. The results are presented as mean ± SEM. *P < 0.05.
Figure 3. (A) Plasma glucose, (B) glucagon, (C) TAG, (D) NEFA, (E) acetaminophen, and (F) insulin (pmol/L) at fasting (−120 to 0 minutes) and in response to a mixed meal and acetaminophen (consumed at 0 minutes) at the end of 4 weeks of treatment with either lixisenatide (white circles) or placebo (black circles) (study two). The lixisenatide or placebo injection was self-administered at −30 minutes. The results are presented as mean ± SEM. *P < 0.05.CC BY · PubMed Central
Figure 4. (A) Total glucose Ra, (B) meal glucose Ra, (C) EGP, and (D) Rd (µmol/kg/min) at fasting (−40 to 0 minutes) and in response to a mixed meal (consumed at 0 minutes) at the end of 4 weeks of treatment with either lixisenatide (white circles) or placebo (black circles) (study two). The lixisenatide or placebo injection was self-administered at −30 minutes. The results are presented as mean ± SEM. *P < 0.05.
Figure 4. (A) Total glucose Ra, (B) meal glucose Ra, (C) EGP, and (D) Rd (µmol/kg/min) at fasting (−40 to 0 minutes) and in response to a mixed meal (consumed at 0 minutes) at the end of 4 weeks of treatment with either lixisenatide (white circles) or placebo (black circles) (study two). The lixisenatide or placebo injection was self-administered at −30 minutes. The results are presented as mean ± SEM. *P < 0.05.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Research works printed but not linked: 2

  1. Distiller, 2008, Pharmacokinetics and pharmacodynamics of GLP-1 agonist AVE0010 in type 2 diabetes patients, Diabetes, 57, A154
  2. Becker, 2010, Restoration of insulin release with lixisenatide in patients with type 2 diabetes, Diabetologia, 53

Cited by

See all 32

Metadata

Authors
Whyte, M. B., Shojaee-Moradie, F., Sharaf, S. E., Jackson, N. C., Fielding, B., Hovorka, R., Mendis, J., Russell-Jones, D., & Umpleby, A. M.
Affiliations
  • University of Surrey (GB)
  • Faculty of Health and Medical Sciences, University of Surrey, Guildford, United Kingdom
  • University of Cambridge (GB)
Corresponding author
Whyte, Martin B
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2018-09-11
Volume
104
Issue
2
Pages
359-368
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2891142526
Cited by
32
References
49
Citations by year
2026: 4 · 2025: 3 · 2024: 4 · 2023: 3 · 2022: 4 · 2021: 6 · 2020: 6 · 2019: 1
FWCI
2.59
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Surrey Research Insight Open Access (The University of Surrey) (submittedVersion)
  • Apollo (University of Cambridge) (submittedVersion)
  • Apollo
Funders
Sanofi
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
lixisenatide, GLP-1 receptor agonists, chylomicron clearance, postprandial lipemia, type 2 diabetes, postprandial blood glucose, gastric emptying, glucose kinetics, hypertriglyceridemia
MeSH terms
Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-2 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Blood Glucose, Chylomicrons, Diabetes Mellitus, Type 2, Double-Blind Method, Gastric Emptying, Humans, Hypoglycemic Agents, Male, Metabolic Clearance Rate, Middle Aged, Peptides, Triglycerides, Treatment Outcome, Cross-Over Studies, Postprandial Period

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lixisenatide Reduces Chylomicron Triacylglycerol by Increased Clearance. https://app.cochat.ai/papers/10.1210/jc.2018-01176
The paper
Whyte, M. B., Shojaee-Moradie, F., Sharaf, S. E., Jackson, N. C., Fielding, B., Hovorka, R., Mendis, J., Russell-Jones, D., & Umpleby, A. M. (2019). Lixisenatide Reduces Chylomicron Triacylglycerol by Increased Clearance. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2018-01176

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.